Solasia Pharma Reports Impairment Loss and Earnings Shortfall for 2024

Solasia Pharma KK ( (JP:4597) ) has shared an update.

Solasia Pharma K.K. has announced an impairment loss for fiscal year 2024 due to challenges in securing a licensing agreement for DARVIAS® in China and limited market penetration for its current indication of peripheral T-cell lymphoma. This has resulted in a revaluation of intangible assets and a recorded impairment loss of 959 million yen, affecting their consolidated earnings, which fell short of previous forecasts.

More about Solasia Pharma KK

Solasia Pharma K.K. operates in the pharmaceutical industry, focusing on the development and commercialization of oncology-focused products. The company is engaged in out-licensing activities, particularly in China, and is advancing preclinical development for its product DARVIAS® to expand its indications.

YTD Price Performance: 21.05%

Average Trading Volume: 304

Technical Sentiment Consensus Rating: Buy

Current Market Cap: €53.48M

Learn more about 4597 stock on TipRanks’ Stock Analysis page.